InspireMD Inc (NASDAQ: NSPR) appointed Kathleen Kennedy as Senior Vice President of Global Sales and Marketing on July 30, 2026, to drive the commercialization of its CGuard Prime carotid stent system. The appointment signals the company's preparation for the planned U.S. market entry of its stroke prevention technology, leveraging Kennedy’s extensive network within vascular and neurovascular physician communities. This leadership addition is critical for InspireMD as it seeks to establish its proprietary MicroNet mesh technology as an industry standard in carotid stenting.

Kennedy reports directly to Chief Executive Officer Marvin Slosman. Her role focuses on building a productive commercial team in anticipation of the potential U.S. approval and commercial relaunch of the CGuard platform, including the CGuard Prime 80cm implant for Transcarotid Artery Revascularization (TCAR) procedures. The company highlighted that her deep expertise in carotid intervention and established relationships with health systems are invaluable for scaling commercial growth.

Executive Background

Kennedy brings more than 30 years of medical device sales leadership experience to the role. She previously served as Sales Director at InspireMD, supporting the initial U.S. launch of CGuard Prime. Before rejoining InspireMD, she held the position of Vice President of Sales for North America at Omniscient Neurotechnology. Her earlier career includes roles as Senior Area Director at Silk Road Medical and Chief Commercial Officer at CAE Healthcare (now Elevate Healthcare). She also held commercial positions at Cordis, Biomet, Guidant Corporation (now Boston Scientific), and Angiodynamics.

"Kathy’s appointment reflects our continued commitment to building a highly talented and productive commercial team," said Slosman. "As we prepare for the potential U.S. approval and commercial relaunch of the CGuard platform, Kathy’s deep expertise in carotid intervention, proven commercial leadership and established relationships throughout the field make her invaluable to our U.S. commercial organization."

Commercial Strategy

The company emphasized the strength of the clinical data behind CGuard and the significant opportunity in the U.S. carotid intervention market. Kennedy stated that her decision to return was driven by the impact of CGuard’s MicroNet mesh technology on patient outcomes. She aims to work with physician partners and hospital customers to expand access to the technology.

InspireMD’s common stock trades on Nasdaq under the ticker symbol NSPR. The company faces various risks associated with recurring losses, negative cash flows, and the uncertainty of regulatory approvals, as detailed in its filings with the Securities and Exchange Commission.

What the Numbers Show

While this announcement does not disclose new financial figures, it highlights a strategic shift toward aggressive commercialization. The return of a leader with prior internal knowledge of the product launch suggests an accelerated timeline for market penetration. Investors should monitor subsequent filings for updates on FDA approval status and capital requirements needed to support the expanded sales force.

InspireMD, Inc. has granted an aggregate of 91,161 shares of restricted stock to six new non-executive employees as an inducement material to their employment. The grants were approved by the Compensation Committee of InspireMD's Board of Directors with a grant date of June 12, 2026.

The Inducement Grants were issued outside of InspireMD's 2021 Equity Incentive Plan and were instead granted under the InspireMD's 2024 Inducement Plan. This plan is used exclusively for equity awards to individuals who were not previously employees of the company, or following a bona fide period of non-employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock vests over a three-year period. One-third of the shares vest on the first anniversary of the grant date, with the remainder vesting in two equal installments on the second and third anniversaries. All vesting is subject to the continued employment of the recipients with InspireMD as of the applicable vesting dates.

Grant Details

InspireMD develops the CGuard Prime carotid stent system for the prevention of stroke and its common stock is quoted on Nasdaq under the ticker symbol NSPR.